180 related articles for article (PubMed ID: 10606360)
1. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Karim A; Tolbert DS; Hunt TL; Hubbard RC; Harper KM; Geis GS
J Rheumatol; 1999 Dec; 26(12):2539-43. PubMed ID: 10606360
[TBL] [Abstract][Full Text] [Related]
2. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
[TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis.
Lafforgue P; Monjanel-Mouterde S; Durand A; Catalin J; Acquaviva PC
J Rheumatol; 1995 May; 22(5):844-9. PubMed ID: 8587070
[TBL] [Abstract][Full Text] [Related]
4. Outcome of specific COX-2 inhibition in rheumatoid arthritis.
Lipsky PE; Isakson PC
J Rheumatol Suppl; 1997 Jul; 49():9-14. PubMed ID: 9249645
[TBL] [Abstract][Full Text] [Related]
5. A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.
Zhang X; Huang Y; Navarro MT; Hisoire G; Caulfield JP
J Clin Pharmacol; 2010 Sep; 50(9):1031-8. PubMed ID: 20100913
[TBL] [Abstract][Full Text] [Related]
6. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
7. Lumiracoxib does not affect methotrexate pharmacokinetics in rheumatoid arthritis patients.
Hartmann SN; Rordorf CM; Milosavljev S; Branson JM; Chales GH; Juvin RR; Lafforgue P; Le Parc JM; Tavernier CG; Meyer OC
Ann Pharmacother; 2004 Oct; 38(10):1582-7. PubMed ID: 15340127
[TBL] [Abstract][Full Text] [Related]
8. Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis.
Gumbhir-Shah K; Cevallos WH; DeCleene SA; Korth-Bradley JM
J Rheumatol; 1996 Jun; 23(6):984-9. PubMed ID: 8782127
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate.
Carmichael SJ; Beal J; Day RO; Tett SE
J Rheumatol; 2002 Oct; 29(10):2077-83. PubMed ID: 12375315
[TBL] [Abstract][Full Text] [Related]
10. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Wolfe F; Michaud K; Burke TA; Zhao SZ
J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Tindall E
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
[TBL] [Abstract][Full Text] [Related]
12. The effect of ingestion of ferrous sulfate on the absorption of oral methotrexate in patients with rheumatoid arthritis.
Hamilton SF; Campbell NR; Kara M; Watson J; Connors M
J Rheumatol; 2003 Sep; 30(9):1948-50. PubMed ID: 12966595
[TBL] [Abstract][Full Text] [Related]
13. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg.
Kremer JM; Hamilton RA
J Rheumatol; 1995 Nov; 22(11):2072-7. PubMed ID: 8596147
[TBL] [Abstract][Full Text] [Related]
14. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis.
Wolfe F; Flowers N; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 May; 29(5):1015-22. PubMed ID: 12022317
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
Kusunoki N; Yamazaki R; Kawai S
Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
[TBL] [Abstract][Full Text] [Related]
16. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen.
Ta LE; Dionne RA
Pain; 2004 Sep; 111(1-2):13-21. PubMed ID: 15327804
[TBL] [Abstract][Full Text] [Related]
17. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
Vakily M; Amer F; Kukulka MJ; Andhivarothai N
J Clin Pharmacol; 2005 Oct; 45(10):1179-86. PubMed ID: 16172183
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
19. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
[TBL] [Abstract][Full Text] [Related]
20. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
